JANX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Janux Therapeutics Inc (JANX) is not a strong buy for a beginner, long-term investor at this time. The stock faces significant execution risks, insider and hedge fund selling, and mixed financial performance. While there are no immediate positive catalysts, the stock may warrant monitoring for future developments.
The technical indicators are mixed. The MACD is positive and expanding, suggesting some bullish momentum. However, the RSI is neutral at 43.303, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support and resistance levels indicate limited upside potential in the near term, with a pivot at 13.184 and resistance at 13.963.
The company's revenue increased significantly by 2177.90% YoY in Q3 2025, showcasing potential growth in its operations. Gross margin remains strong at 100%.
Analysts have downgraded the stock, citing execution risks and lack of clear data on key drugs (JANX007 and JANX008). Hedge funds and insiders are selling heavily, with hedge fund selling up 575.67% and insider selling up 137.72%. No recent news or congress trading data supports the stock.
In Q3 2025, revenue increased significantly to $10 million, but net income dropped to -$24.31 million (-13.35% YoY), and EPS fell to -0.39 (-23.53% YoY). The company is still operating at a loss, which may concern long-term investors.
Analysts have lowered price targets significantly, with the most recent downgrade by Clear Street to Hold from Buy, with a price target of $12 (down from $32). Other analysts have also reduced price targets, citing mixed data on JANX007 and execution risks. The overall sentiment is cautious, with elevated risks highlighted.
